Literature DB >> 34033104

A Luminescence Assay to Quantify Cell Viability in Real Time.

Peter Hofsteen1, Natasha Karassina1, James J Cali1, Jolanta Vidugiriene2.   

Abstract

Comprehensive understanding of cellular responses to changes in the cellular environment or by drug treatment requires time-dependent analysis ranging from hours to several days. Here, we describe a sensitive, nonlytic live-cell assay that allows continuous or 'real-time' monitoring of cell viability, growth, and cytotoxicity over an extended period of time. We illustrate the use of the assay for small drug molecule and antibody-dependent cytotoxicity studies using cancer cells in 384-well plates. We show that the ability to measure changes in live cells over time provides instantaneous information on the biological status of the cells, information about the mode of action of the drug, and offers an added advantage of preserving the cells for multiplexing with downstream applications.

Entities:  

Keywords:  ADC; Antibody-dependent cytotoxicity; Continuous viability measurements; Live cell viability assay; Real-time cell viability assay; Time-dependent cytotoxicity

Year:  2021        PMID: 34033104     DOI: 10.1007/978-1-0716-1162-3_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Properties and reaction mechanism of the bioluminescence system of the deep-sea shrimp Oplophorus gracilorostris.

Authors:  O Shimomura; T Masugi; F H Johnson; Y Haneda
Journal:  Biochemistry       Date:  1978-03-21       Impact factor: 3.162

Review 3.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Authors:  Peter Atadja
Journal:  Cancer Lett       Date:  2009-04-02       Impact factor: 8.679

Review 4.  NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence.

Authors:  Christopher G England; Emily B Ehlerding; Weibo Cai
Journal:  Bioconjug Chem       Date:  2016-04-19       Impact factor: 4.774

5.  Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate.

Authors:  Mary P Hall; James Unch; Brock F Binkowski; Michael P Valley; Braeden L Butler; Monika G Wood; Paul Otto; Kristopher Zimmerman; Gediminas Vidugiris; Thomas Machleidt; Matthew B Robers; Hélène A Benink; Christopher T Eggers; Michael R Slater; Poncho L Meisenheimer; Dieter H Klaubert; Frank Fan; Lance P Encell; Keith V Wood
Journal:  ACS Chem Biol       Date:  2012-08-30       Impact factor: 5.100

6.  Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Authors:  Mark Barok; Minna Tanner; Katri Köninki; Jorma Isola
Journal:  Breast Cancer Res       Date:  2011-04-21       Impact factor: 6.466

7.  Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening.

Authors:  Sarah J Duellman; Wenhui Zhou; Poncho Meisenheimer; Gediminas Vidugiris; James J Cali; Prson Gautam; Krister Wennerberg; Jolanta Vidugiriene
Journal:  Assay Drug Dev Technol       Date:  2015-09-18       Impact factor: 1.738

8.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.